Zacks Small Cap Increases Earnings Estimates for Soligenix

Soligenix, Inc. (NASDAQ:SNGX) – Research analysts at Zacks Small Cap increased their FY2024 EPS estimates for shares of Soligenix in a research note issued on Monday, November 11th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will earn ($4.65) per share for the year, up from their previous estimate of ($5.10). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share.

Soligenix Stock Down 3.8 %

Shares of NASDAQ SNGX opened at $3.54 on Thursday. The business’s 50 day moving average is $3.76 and its two-hundred day moving average is $4.34. Soligenix has a 52-week low of $1.83 and a 52-week high of $32.00. The firm has a market cap of $8.89 million, a price-to-earnings ratio of -0.47 and a beta of 1.85.

Hedge Funds Weigh In On Soligenix

Institutional investors have recently bought and sold shares of the company. OLD National Bancorp IN purchased a new stake in shares of Soligenix during the second quarter worth $26,000. Stephens Inc. AR purchased a new position in Soligenix in the third quarter valued at $184,000. Finally, Armistice Capital LLC acquired a new position in Soligenix during the 2nd quarter worth $206,000. 3.60% of the stock is owned by institutional investors and hedge funds.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.